Genzyme Fabrazyme approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFDA approves Genzyme's Fabrazyme (agalsidase beta) April 24 as the first treatment for Fabry disease. Orphan drug exclusivity will presumably prevent approval of Transkaryotic Therapies' Replagal (agalsidase alfa) through 2010. Approximately 5,000 people worldwide have the disorder, with "over 700 patients" currently diagnosed in the U.S. Genzyme hopes to build the market by targeting the 0.2% of dialysis patients that could have the rare disease and through increased genetic screening. The firm also plans to shift towards treatment initiation at the time of diagnosi
You may also be interested in...
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.
Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.